ArticleScientific reports2025
Identification of plasma extracellular vesicle protein biomarkers in diabetic retinopathy progression.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Glycosylation of Extracellular Vesicles: Analytical and Translational Insights into Biomarker Discovery and Regenerative Medicine.International journal of molecular sciences · 2026Review
- Oxidative Stress in Diabetic Retinopathy: Pathogenic Mechanisms, Biomarkers and Clinical Implications.Antioxidants (Basel, Switzerland) · 2026Review
- Exosome-mediated cell-cell communication: a new perspective on the mechanisms and therapeutic potential of diabetic microvascular complications.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein biomarkers from plasma extracellular vesicles (EVs) have been extensively identified in various diseases. To explore biomarkers associated with diabetic retinopathy (DR) progression, we designed two cohorts, discovery and validation cohorts, including four groups: healthy control, type 2 diabetes mellitus, non-proliferative DR (NPDR), and proliferative DR (PDR). A total of 32 differentially expressed proteins (DEPs) were screened by proteomic analysis in the four groups of the discovery cohort. Among them, four hub proteins, CELA3A, CELA3B, GLUD1, and CTRC, were identified to be related to DR progression, and their correlation with clinical characteristics was further analyzed. Subsequently, enzyme-linked immunosorbent assay in the validation cohort confirmed that the expression levels of CELA3A, CELA3B, and CTRC were consistent with the proteomic results. Receiver operator characteristic curve analysis found that the AUC values of three hub proteins and their composed panels distinguishing NPDR/PDR from DM were all > 0.7, except for DM-NPDR of CELA3B. In addition, CELA3A, CELA3B, and CTRC proteins were significantly correlated with some clinical indicators of DR. This study indicates that the plasma EV proteins CELA3A, CELA3B, and CTRC are expected to become biomarkers to monitor DR progression and provide guidance for DR diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.